News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
UK’s NICE Rejects GlaxoSmithKline, Genmab A/S Leukemia Drug, Arzerra
June 24, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- GlaxoSmithKline leukemia drug Arzerra, licensed from Denmark's Genmab, has been rejected by Britain's cost watchdog NICE in preliminary draft guidance.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
GSK
MORE ON THIS TOPIC
Adcomms
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm
May 22, 2026
·
2 min read
·
Tristan Manalac
Insights
Inside Germany’s biotech capital infrastructure and innovation engine
May 21, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Regulatory
Pazdur declines to announce candidacy for vacated FDA commissioner role
May 20, 2026
·
4 min read
·
Heather McKenzie
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
May 20, 2026
·
1 min read
·
Jef Akst
